314 related articles for article (PubMed ID: 29877615)
1. Effectiveness and cost of radiofrequency ablation and stereotactic body radiotherapy for treatment of early-stage hepatocellular carcinoma: An analysis of SEER-medicare.
Parikh ND; Marshall VD; Green M; Lawrence TS; Razumilava N; Owen D; Singal AG; Feng M
J Med Imaging Radiat Oncol; 2018 Oct; 62(5):673-681. PubMed ID: 29877615
[TBL] [Abstract][Full Text] [Related]
2. Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database.
Rajyaguru DJ; Borgert AJ; Smith AL; Thomes RM; Conway PD; Halfdanarson TR; Truty MJ; Kurup AN; Go RS
J Clin Oncol; 2018 Feb; 36(6):600-608. PubMed ID: 29328861
[TBL] [Abstract][Full Text] [Related]
3. Retrospective analysis of stereotactic body radiation therapy efficacy over radiofrequency ablation for hepatocellular carcinoma.
Kim N; Kim HJ; Won JY; Kim DY; Han KH; Jung I; Seong J
Radiother Oncol; 2019 Feb; 131():81-87. PubMed ID: 30773192
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic body radiation therapy vs. radiofrequency ablation in Asian patients with hepatocellular carcinoma.
Kim N; Cheng J; Jung I; Liang J; Shih YL; Huang WY; Kimura T; Lee VHF; Zeng ZC; Zhenggan R; Kay CS; Heo SJ; Won JY; Seong J
J Hepatol; 2020 Jul; 73(1):121-129. PubMed ID: 32165253
[TBL] [Abstract][Full Text] [Related]
5. Radiotherapy for Hepatocellular Carcinoma Results in Comparable Survival to Radiofrequency Ablation: A Propensity Score Analysis.
Hara K; Takeda A; Tsurugai Y; Saigusa Y; Sanuki N; Eriguchi T; Maeda S; Tanaka K; Numata K
Hepatology; 2019 Jun; 69(6):2533-2545. PubMed ID: 30805950
[TBL] [Abstract][Full Text] [Related]
6. Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma.
Wahl DR; Stenmark MH; Tao Y; Pollom EL; Caoili EM; Lawrence TS; Schipper MJ; Feng M
J Clin Oncol; 2016 Feb; 34(5):452-9. PubMed ID: 26628466
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of Computed Tomography- Versus Ultrasound-Guided Percutaneous Radiofrequency Ablation Among Medicare Patients 65 Years of Age or Older With Hepatocellular Carcinoma.
Huo J; Aloia TA; Xu Y; Chung TH; Sheu T; Tina Shih YC
Value Health; 2019 Mar; 22(3):284-292. PubMed ID: 30832966
[TBL] [Abstract][Full Text] [Related]
8. Differences in Survival Between First-Line Radiofrequency Ablation versus Surgery for Early-Stage Hepatocellular Carcinoma: A Population Study Using the Surveillance, Epidemiology, and End Results Database.
Lin Y; Pan XB
Med Sci Monit; 2020 May; 26():e921782. PubMed ID: 32461542
[TBL] [Abstract][Full Text] [Related]
9. Optimal application of stereotactic body radiotherapy and radiofrequency ablation treatment for different multifocal hepatocellular carcinoma lesions in patients with Barcelona Clinic Liver Cancer stage A4-B1: a pilot study.
Wang F; Numata K; Takeda A; Ogushi K; Fukuda H; Nihonmatsu H; Hara K; Chuma M; Tsurugai Y; Maeda S
BMC Cancer; 2021 Oct; 21(1):1169. PubMed ID: 34717577
[TBL] [Abstract][Full Text] [Related]
10. Radiofrequency ablation and stereotactic body radiotherapy for hepatocellular carcinoma: should they clash or reconcile?
Rim CH; Lee HY; Kim JS; Kim H
Int J Radiat Biol; 2021; 97(2):111-119. PubMed ID: 33253598
[TBL] [Abstract][Full Text] [Related]
11. Comparison of clinical outcome between stereotactic body radiotherapy and radiofrequency ablation for unresectable hepatocellular carcinoma.
Ji R; Ng KK; Chen W; Yang W; Zhu H; Cheung TT; Chiang CL; Wong TCL; Kong FM; Wu G; Lo CM
Medicine (Baltimore); 2022 Jan; 101(4):e28545. PubMed ID: 35089192
[TBL] [Abstract][Full Text] [Related]
12. Radiofrequency ablation versus stereotactic body radiotherapy for hepatocellular carcinoma: a meta-analysis.
Zhang H; Chang N; Han T; Ma S; Qu G; Liu H; Sun C; Cheng C; Zhou Q; Sun Y
Future Oncol; 2021 Oct; 17(30):4027-4040. PubMed ID: 34278818
[TBL] [Abstract][Full Text] [Related]
13. Radiofrequency Ablation
Xu J; Noda C; Erickson A; Mokkarala M; Charalel R; Ramaswamy R; Tao YU; Akinwande O
Anticancer Res; 2018 Nov; 38(11):6381-6386. PubMed ID: 30396961
[TBL] [Abstract][Full Text] [Related]
14. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.
Parikh ND; Marshall VD; Singal AG; Nathan H; Lok AS; Balkrishnan R; Shahinian V
Hepatology; 2017 Jan; 65(1):122-133. PubMed ID: 27770556
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiotherapy vs radiofrequency ablation for the treatment of hepatocellular carcinoma: a meta-analysis.
Facciorusso A; Chierici A; Cincione I; Sacco R; Ramai D; Mohan BP; Chandan S; Ofosu A; Cotsoglou C
Expert Rev Anticancer Ther; 2021 Jun; 21(6):681-688. PubMed ID: 33590783
[No Abstract] [Full Text] [Related]
16. Radiofrequency ablation versus surgical resection of hepatocellular carcinoma: contemporary treatment trends and outcomes from the United States National Cancer Database.
Uhlig J; Sellers CM; Stein SM; Kim HS
Eur Radiol; 2019 May; 29(5):2679-2689. PubMed ID: 30560364
[TBL] [Abstract][Full Text] [Related]
17. Cost Effectiveness Analysis of Radiofrequency Ablation (RFA) Versus Stereotactic Body Radiotherapy (SBRT) for Early Stage Renal Cell Carcinoma (RCC).
Donovan EK; Xie F; Louie AV; Chu W; Siva S; Kapoor A; Swaminath A
Clin Genitourin Cancer; 2022 Oct; 20(5):e353-e361. PubMed ID: 35490099
[TBL] [Abstract][Full Text] [Related]
18. Comparisons between radiofrequency ablation and stereotactic body radiotherapy for liver malignancies: Meta-analyses and a systematic review.
Lee J; Shin IS; Yoon WS; Koom WS; Rim CH
Radiother Oncol; 2020 Apr; 145():63-70. PubMed ID: 31923711
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic body radiotherapy versus radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis.
Wang L; Ke Q; Huang Q; Shao L; Chen J; Wu J
Int J Hyperthermia; 2020; 37(1):1313-1321. PubMed ID: 33243024
[TBL] [Abstract][Full Text] [Related]
20. Comparative assessment of the safety and effectiveness of radiofrequency ablation among elderly medicare beneficiaries with hepatocellular carcinoma.
Massarweh NN; Park JO; Yeung RS; Flum DR
Ann Surg Oncol; 2012 Apr; 19(4):1058-65. PubMed ID: 21947695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
